TGA reaches final decision on DMAA

The Therapeutic Goods Administration (TGA) has made its final decision on DMAA scheduling. DMAA (1,3-dimethylamylamine) is an ingredient in some sports supplements and ‘party pills’ and acts as a stimulant, giving an adrenaline-like high.

Those who use DMAA may experience adverse health effects such as high blood pressure, headaches, vomiting, cerebral haemorrhage, stroke and even death. DMAA was banned from all products in New Zealand in April.

The TGA has decided that DMAA should be included in Appendix C of the Poisons Standard, which means that the sale, supply and use of DMAA will be prohibited.

Following advice from the Advisory Committee on Medicines Scheduling (ACMS) and public consultation, and in response to safety concerns about the abuse of DMAA, the TGA announced its decision on 1 August.

State and territory authorities will be responsible for enforcing the scheduling decision.

For more information on DMAA, visit the FSANZ (Food Standards Australia New Zealand) website.

This information is reproduced with kind permission of FSANZ.